Search

Your search keyword '"Haggiag, Shalom"' showing total 233 results

Search Constraints

Start Over You searched for: Author "Haggiag, Shalom" Remove constraint Author: "Haggiag, Shalom"
233 results on '"Haggiag, Shalom"'

Search Results

6. Models of care in emergency neurology: from the Neuro Fast Track to the emergency neurologist—a position paper of the Italian Association for Emergency Neurology (ANEU)

13. Correction to: Monoallelic KIF1A-related disorders: a multicenter cross sectional study and systematic literature review

14. Monoallelic KIF1A-related disorders: a multicenter cross sectional study and systematic literature review

17. Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies

18. Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study

21. Exit strategies for “needle fatigue” in multiple sclerosis: a propensity score-matched comparison study

23. Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study.

24. Informal caregiver's socio demographic profile for community-dwelling women and men with mild to moderate Alzheimer's disease, compliance, and satisfaction to treatment: A post-hoc analysis of the AXEPT study.

26. Correction to: Monoallelic KIF1A-related disorders: a multicenter cross sectional study and systematic literature review

27. Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose

28. Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies

29. Stopping disease-modifying treatments in multiple sclerosis: a meta-analysis with meta-regression

30. The first case of meningitis associated with SARS-CoV-2 BA.2 variant infection with persistent viremia

32. Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis

33. Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study

35. Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies.

36. Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis

38. Shift of multiple sclerosis onset towards older age

41. Correction to: Monoallelic KIF1A-related disorders: a multicenter cross sectional study and systematic literature review

43. Monoallelic KIF1A-related disorders: a multicenter cross sectional study and systematic literature review

44. Scoring the 10‐year risk of ambulatory disability in multiple sclerosis: the RoAD score

46. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

47. MSJ964778_Appendix – Supplemental material for Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regression

50. Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies.

Catalog

Books, media, physical & digital resources